Vincent Cottin

Jan 2, 2025 | mdpi.com | Vincent Cottin

3. Results 3.1. Study PopulationAmong 144 serum samples with anti-Ku antibodies detected using the dot assay, 31 were associated with patients presenting diffuse abnormalities on chest CT scan (Figure 1). Upon further review of the immunology data, 10 cases were considered false positives based on an inconsistent indirect immunofluorescence pattern on HEp-2 cells (Figure 2) or low intensity close to the positivity threshold.

Dec 31, 2024 | respiratory-research.biomedcentral.com | Athol U Wells |Ayodeji Adegunsoye |Vincent Cottin |Sonye Danoff |Anand Devaraj |Kevin Flaherty | +7 more

Surveys were completed between March 2022 and July 2023. The international guideline on the definition of PPF [1] was published between distribution of the first and second rounds of the survey. The first survey was sent to 405 physicians in 32 countries and completed by 207, of whom 131 completed the second round and 94 completed the third round. The clinical experience of the respondents is summarised in Table S1 in Additional file 1.

Dec 4, 2024 | bmjopenrespres.bmj.com | Luca Richeldi |Arata Azuma |Vincent Cottin |Michael Kreuter

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive disease associated with a decline in lung function and early mortality. In a phase II trial, treatment with the oral preferential phosphodiesterase 4B inhibitor, BI 1015550, prevented a decline in lung function over 12 weeks and had an acceptable safety profile in patients with IPF, regardless of background use of antifibrotics, supporting phase III clinical development.

Aug 29, 2024 | erj.ersjournals.com | Joan A. Barbera |Vincent Cottin |Sergio Harari |Joanna Pepke-Zaba

IntroductionIt has long been known that chronic lung disease (CLD) is frequently complicated by pulmonary hypertension (PH) and right ventricular (RV) dysfunction. Despite this clear association, the prevalence, clinical significance and treatment options for PH in CLD are still under investigation. The heterogeneity of PH in CLD increases the difficulty in characterising this group. In addition, the definitions of PH in general have evolved.

Aug 13, 2024 | digitalcommons.library.tmc.edu | Toby Maher |Shervin Assassi |Arata Azuma |Vincent Cottin

INTRODUCTION: Progressive pulmonary fibrosis (PPF) includes any diagnosis of progressive fibrotic interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis (IPF). However, disease progression appears comparable between PPF and IPF, suggesting a similar underlying pathology relating to pulmonary fibrosis. Following positive results in a phase II study in IPF, this phase III study will investigate the efficacy and safety of BI 1015550 in patients with PPF (FIBRONEER-ILD).